European perspectives in         personalised medicineRuxandra Draghia-Akli, Director for Health ResearchDirectorate-Gener...
Not here to preach to the choir…• We are here to explore  how we can make music  together• We are here to listen and  lear...
Personalised medicine: the time for  action is now• Rapidly emerging area with  high potential for Europe• Raising questio...
EC stocktaking exercise: personalised  medicine workshops and conference• Vision for Europe 2020: identify bottlenecks for...
noitavonnI                                   dna hcrayciloP                                           eseR P              ...
noitavonnI                               dna hcrayciloP                                       eseR P                    se...
Current EC health research activities   • Around €1 billion to     collaborative research     enabling the development    ...
Personalised medicine: our current  research focus (period 2010 – 2012)• Technologies for patient stratification/personali...
Examples of EU-funded research                          CAGEKIDMETAHIT                          Cancer Genomics of the    ...
International Rare Diseases Research Consortium                    (IRDiRC)            Ambitious 2020 goals           200 ...
IMI: enabling personalised medicine approaches – 3 project examples      U-BIOPRED: Unbiased BIOmarkers in      PREDiction...
gro.NOITADNUOF-GNUL-NAEPORUE.DERPOIBU.www                   -Clinical data from a large group of                    asthma...
Horizon 2020: The next framework  programme for research and innovation• Europe needs cutting edge  research and innovatio...
noitavonnI                                                            dna hcrayciloP                                      ...
Some key questions for discussion• How can bioclusters/bioregions support the rapid uptake of  personalised medicine?• How...
More information including workshop and conference reportsVisit us online: http://ec.europa.eu/research/health            ...
noitavonnI             dna hcrayciloP                     eseR PThank you for your attention
Upcoming SlideShare
Loading in …5
×

European Perspectives in Personalised Medicine

667 views

Published on

EuroBioForum 2012 | 18 April 2012
Presentation by Ruxandra Draghia-Akli, Director Directorate Health, DG Research and Innovation, European Commission

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
667
On SlideShare
0
From Embeds
0
Number of Embeds
18
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

European Perspectives in Personalised Medicine

  1. 1. European perspectives in personalised medicineRuxandra Draghia-Akli, Director for Health ResearchDirectorate-General for Research and InnovationEuropean Commission dna hcraeseR noitavonnI
  2. 2. Not here to preach to the choir…• We are here to explore how we can make music together• We are here to listen and learn from each other• EU level coordination can help in the implementation of personalised medicine dna hcrayciloP eseR P noitavonnI
  3. 3. Personalised medicine: the time for action is now• Rapidly emerging area with high potential for Europe• Raising questions along the full innovation cycle• Potentially great benefits for patients• Potentially large economic impact across public and private sectors dna hcrayciloP eseR P noitavonnI
  4. 4. EC stocktaking exercise: personalised medicine workshops and conference• Vision for Europe 2020: identify bottlenecks for implementation and research needs at European level• 2010: Preparatory workshops (-omics, biomarkers, clinical trials/regulatory, uptake)• 2011: European Perspectives in Personalised Medicine conference dna hcrayciloP eseR P noitavonnI
  5. 5. noitavonnI dna hcrayciloP eseR P snoitalupop llams ro/dna deifitarts rof seigolodohtem lairt lacinilc detpadA • seipareht gnitsixe ni srekramoib fo esu retteB • srekramoib fo sepyt lla fo noitadilav lacinilc dna noitacifilauQ • srekramoib fo noitadilav dna noitacifitnedi rof seigolodohtem dna sehcaorppa wen fo tnempoleveD • • Translating knowledge to medical applications serutangis xelpmoc erolpxe ot smhtirogla levon fo tnempoleved dna seliforp ralucelom htiw atad lacinilc gnikniL •serudecorp lacitylana dna noitcelloc elpmas dna atad rof sdradnatS • sgnittes lacinilc ni esu rof sloot hcraeser wen fo snoitatpadA • • Generating knowledge and developing the right tools key challenges for research (1/2) Outcome of our stock taking exercise:
  6. 6. noitavonnI dna hcrayciloP eseR P sehcaorppa enicidem desilanosrep no seiduts cimonoce-ocamrahp rehto dna ssenevitceffe tsoc evitarapmoC • tnemssessA ygolonhceT htlaeH rof seigolodohteM • smetsys erac htlaeh ni sehcaorppa desilanosrep fo ytilibaiv cimonoce eht no dna stneitap rof tcapmi no seidutS • • Understanding the economic impacts and aspectsalucirruc gniniart dna noitacude ni egdelwonk wen fo noitargetnI • sredlohekats dna senilpicsid tnereffid neewteb noissucsid dna noitaroballoC • • Breaking barriers and speaking the same language key challenges for research (2/2) Outcome of our stock taking exercise:
  7. 7. Current EC health research activities • Around €1 billion to collaborative research enabling the development of personalised medicine approaches JRC (EC) Euratom 1.8 Capacities 4.1 4.3 Cooperation People 4.7 32.3 7. 5 IdeasTotal FP7 budget: € 54.6 billionHealth Priority in Cooperation: € 6.1 billion dna hcrayciloP eseR P noitavonnI
  8. 8. Personalised medicine: our current research focus (period 2010 – 2012)• Technologies for patient stratification/personalised medicine• Genome based biomarkers for patient stratification and pharmacogenomic strategies• Human epigenomics• Validation of –omics based biomarkers• Rare diseases as a model for personalised medicine• Clinical bioinformatics• Statistical methods for collection and analysis of – omics data• New methodologies for Health Technology Assessment dna hcrayciloP eseR P noitavonnI
  9. 9. Examples of EU-funded research CAGEKIDMETAHIT Cancer Genomics of the European ResearchMetagenomics of the Kidney initiative to develop ImagingHuman Intestinal Tract Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic substances TRANSBIG European Network for MINDACT- Microarray In Node negative Genetic and Genomic Disease may Avoid ChemoTherapy Epidemiology dna hcrayciloP eseR P noitavonnI
  10. 10. International Rare Diseases Research Consortium (IRDiRC) Ambitious 2020 goals 200 New Therapies Diagnosis For Most Rare Diseases 23 committed members EU investment over € 430 million dna hcrayciloP eseR P noitavonnI
  11. 11. IMI: enabling personalised medicine approaches – 3 project examples U-BIOPRED: Unbiased BIOmarkers in PREDiction of respiratory disease outcomes PROactive: physical activity as a crucial patient reported outcome in COPDDIRECT: DIabetes REsearCh onpatient straTification dna hcrayciloP eseR P noitavonnI
  12. 12. gro.NOITADNUOF-GNUL-NAEPORUE.DERPOIBU.www -Clinical data from a large group of asthma patients and healthy people - “-omics” technology - Animal and laboratory models - Human challenge models Systems biology Handprint of characteristics that can be observed (“phenotypes”)Thorax, 23.11.10 to better classify severe asthma dna hcrayciloP eseR P noitavonnI
  13. 13. Horizon 2020: The next framework programme for research and innovation• Europe needs cutting edge research and innovation• Essential to ensure competitiveness, growth and jobs• Vital to tackle pressing societal challenges• 3% of GDP invested in R&D: headline target of Europe 2020 dna hcrayciloP eseR P noitavonnI
  14. 14. noitavonnI dna hcrayciloP eseR P esaesid gnitaerT • noitciderp dna tnemeganam esaesid gnivorpmi rof enicidem ocilis-ni gnisU • .sehcaorppa dna seigolonhcet evitavonni dna ,ecitcarp tseb fo noitanimessid • Improving diagnosis dna gnikam noisiced desab ecnedive hguorht seitilauqeni gnicuder dna smetsys erachtlaeh seniccav evitneverp retteb gnipoleveD • fo ssenevitceffe dna ycneiciffe eht gnisimitpO • erac detargetni gnitomorP • • Understanding disease htlaeh fo tnemeganam-fles rof tnemrewopme laudividnI • ssenderaperp dna ecnallievrus gnivorpmI • gnivil detsissa dna tnednepedni ,gniega evitcA • ytilibitpecsus sdeen yrotaluger dna gnikam ycilop esaesid fo tnemssessa eht gnivorpmi dnatroppus ot sdohtem dna sloot cifitneics gnivorpmI • semmargorp gnineercs evitceffe gnipoleveD • atad htlaeh fo esu retteB • ;noitneverp esaesid dna noitomorp htlaeh gnivorpmi ,)srotcaf snoitca noitavonni elbalacs detaler etamilc dna latnemnorivne gnidulcni( dna ecitcarp lacinilc ot egdelwonk gnirrefsnarT • htlaeh fo stnanimreted eht gnidnatsrednU • Wellbeing Challenge – proposal ~ €8.5bn Health, Demographic Change and Horizon 2020:
  15. 15. Some key questions for discussion• How can bioclusters/bioregions support the rapid uptake of personalised medicine?• How can bioclusters/bioregions help proving the value of personalised medicine approaches in healthcare?• What incentives could be developed to stimulate innovation in personalised medicine approaches?• How can rapid integration of innovative technologies/approaches be assured while ensuring quality and safety for patients? dna hcrayciloP eseR P noitavonnI
  16. 16. More information including workshop and conference reportsVisit us online: http://ec.europa.eu/research/health dna hcrayciloP eseR noitavonnI P
  17. 17. noitavonnI dna hcrayciloP eseR PThank you for your attention

×